mAB 4-8

A human monoclonal anti-NTD (SARS-CoV-2 Spike) antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

mAB 4-8 is a human monoclonal antibody targeting SARS-CoV-2 Spike N-terminal domain glycan-free site (Cerutti et al., 2021). It neutralized SARS-CoV-2 live virus with an IC50 of 0.009 μg/ml in vitro (Liu et al., 2020).


Supporting references

Link Tested on Impact factor Notes Publication date
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Spike protein Animal model In vitro Antibody
in vitro binding assay; Vero cells; golden Syrian hamsters; SARS-CoV-2 strain USA-WA1/2020 42.78

Neutralized SARS-CoV-2 live virus with an IC50 of 0.009 μg/ml in vitro. It neutralized a Spike-pseudotyped virus, as well.

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Spike protein Cryo-EM Crystallization Biophysical assay In vitro Antibody
in vitro biophysical assay; crystallization; cryo-EM; Vero E6; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 live virus 15.92

Targets a SARS-CoV-2 Spike protein N-terminal domain supersite. The site is glycan-free and electropositive and is recognized by multiple neutralizing antibodies (the epitopes are overlapping but the recognition might differ).